英夫利昔单抗治疗IVIG无反应型川崎病的进展
Progress in the Treatment of IVIG-Resistant Kawasaki Disease with Infliximab
DOI: 10.12677/ACRP.2020.82004, PDF,   
作者: 宋木雯, 余更生：重庆医科大学附属儿童医院，重庆
关键词: IVIG无反应型川崎病；英夫利昔单抗；综述；IVIG-Resistant Kawasaki Disease； Infliximab； Reviews
摘要: 川崎病(Kawasaki disease, KD)是一种以全身性血管炎为特征的急性自限性疾病，病因尚不清楚，静脉注射丙种球蛋白(intravenous immunoglobulin, IVIG)联合阿司匹林治疗可缓解川崎病的炎症反应，但仍有部分患者对治疗无反应，本文主要针对英夫利昔单抗在IVIG无反应型川崎病中的应用进行综述。
Abstract: Kawasaki disease is an acute self-limited disease characterized by systemic vasculitis; etiology is unclear; intravenous immunoglobulin and aspirin therapy can alleviate the inflammation of Kawasaki disease, but there are still some patients do not respond to treatment. This review focuses on the application of infliximab in IVIG reactive Kawasaki disease.
文章引用：宋木雯, 余更生. 英夫利昔单抗治疗IVIG无反应型川崎病的进展[J]. 亚洲儿科病例研究, 2020, 8(2): 18-22. https://doi.org/10.12677/ACRP.2020.82004

参考文献

[1] Yeun, K.K. and Soo, K.D. (2016) Recent Advances in Kawasaki Disease. Yonsei Medical Journal, 57, 15.
[Google Scholar] [CrossRef] [PubMed]
[2] Campbell, A.J. and Burns, J.C. (2016) Adjunctive Therapies for Kawasaki Disease. Journal of Infection, 72, S1-S5.
[Google Scholar] [CrossRef] [PubMed]
[3] Saneeymehri, S., Baker, K. and So, T.Y. (2015) Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease. Journal of Pediatric Pharmacology & Therapeutics, 20, 163-177.
[4] Singh, S., Vignesh, P. and Burgner, D. (2015) The Epidemiology of Kawasaki Disease: A Global Update. Archives of Disease in Childhood, 100, 1084-1088.
[5] Wallace, C.A., French, J.W., Kahn, S.J., et al. (2000) Initial Intravenous Gammaglobulin Treatment Failure in Kawasaki Disease. Pediatrics, 105, e78.
[Google Scholar] [CrossRef] [PubMed]
[6] Kim, T.Y., Choi, W.S., Woo, C.W., et al. (2007) Predictive Risk Factors for Coronary Artery Abnormalities in Kawasaki Disease. European Journal of Pediatrics, 166, 421-425.
[Google Scholar] [CrossRef] [PubMed]
[7] Kaida, Y., Kambe, T., Kishimoto, S., Koteda, Y., Suda, K., Yamamoto, R., Imai, T., Hazama, T., Takamiya, Y., Shibata, R., Nishida, H., Okuda, S. and Fukami, K. (2017) Efficacy and Safety of Plasma Exchange for Kawasaki Disease with Coronary Artery Dilatation. Renal Replacement Therapy, 3, Article No. 50.
[Google Scholar] [CrossRef] 
[8] Hamada, H., Suzuki, H., Abe, J., et al. (2012) Inflammatory Cytokineprofiles during Cyclosporin Treatment for Immunoglobulin-Resistant Kawasaki Disease. Cytokine, 60, 681-685.
[Google Scholar] [CrossRef] [PubMed]
[9] Newburger, J.W., Takahashi, M. and Burns, J.C. (2016) The Present and Future: Kawasaki Disease. Journal of the American College of Cardiology, 67, 1738-1749.
[Google Scholar] [CrossRef] [PubMed]
[10] Wang, Y., Wang, W., Gong, F., et al. (2013) Evaluation of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions in Relation to Th1/Th2 Cytokine Profiles in Patients with Kawasaki Disease. Arthritis & Rheumatology, 65, 805-814.
[Google Scholar] [CrossRef] [PubMed]
[11] Takahashi, K., Oharaseki, T. and Yokouchi, Y. (2014) Update on Etio and Immunopathogenesis of Kawasaki Disease. Current Opinion in Rheumatology, 26, 31-36.
[Google Scholar] [CrossRef] 
[12] Agarwal, S. and Agrawal, D.K. (2016) Kawasaki Disease: Etiopathogenesis and Novel Treatment Strategies. Expert Review of Clinical Immunology, 13, 247.
[Google Scholar] [CrossRef] 
[13] Hui-Yuen, J.S., Duong, T.T. and Yeung, R.S. (2006) TNF-Alpha Is Necessary for Induction of Coronary Artery Inflammation and Aneurysm Formation in an Animal Model of Kawasaki Disease. The Journal of Immunology, 176, 6294-6301.
[Google Scholar] [CrossRef] [PubMed]
[14] Weiss, J.E., Eberhard, B.A., Chowdhury, D., et al. (2004) Infliximab as a Novel Therapy for Refractory Kawasaki Disease. Journal of Rheumatology, 31, 808-810.
[15] Burns, J.C., Mason, W.H., Hauger, S.B., et al. (2005) Infliximab Treatment for Refractory Kawasaki Syndrome. Journal of Pediatrics, 146, 662-667.
[Google Scholar] [CrossRef] [PubMed]
[16] Son, M.B., Gauvreau, K., Burns, J.C., et al. (2011) Infliximab for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Retrospective Study. Journal of Pediatrics, 158, 644-649.e1.
[Google Scholar] [CrossRef] [PubMed]
[17] Youn, Y., Kim, J., Hong, Y.M., et al. (2015) Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin. Pediatric Infectious Disease Journal, 35, 457.
[Google Scholar] [CrossRef] 
[18] 张鹏宇, 汤楚中, 潘绪, 等. 英夫利西单抗与IVIG治疗IVIG初治无效川崎病效果比较[J]. 中国医学前沿杂志(电子版), 2018, 10(5): 66-69.
[19] Tremoulet, A.H., Jain, S., Jaggi, P., Jimenez-Fernandez, S., Pancheri, J.M., Sun, X., et al. (2014) Infliximab for Intensification of Primary Therapy for Kawasaki Disease: A Phase 3 Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 383, 1731-1738.
[Google Scholar] [CrossRef] 
[20] Nagatomo, K., Muneuchi, J., Nakashima, Y., et al. (2018) Effective Infliximab Therapy for the Early Regression of Coronary Artery Aneurysm in Kawasaki Disease. International Journal of Cardiology, 271, 317-321.
[Google Scholar] [CrossRef] [PubMed]
[21] Nagatomo, Y., et al. (2018) Effective Infliximab Therapy for the Early Regression of Coronary Artery Aneurysm in Kawasaki Disease. International Journal of Cardiology, 271, 317-321.
[22] Hur, G., Song, M.S., Sohn, S., Lee, H.D., Kim, G.B., Cho, H.J., et al. (2019) Infliximab Treatment for Intravenous Immunoglobulin-Resistant Kawasaki Disease: A Multicenter Study in Korea. Korean Circulation Journal, 49, 183-191.
[Google Scholar] [CrossRef] [PubMed]
[23] Shimada, S., Matsuoka, D., Murase, T., et al. (2020) Impact of Infliximab Administration before Plasma Exchange Therapy on Patients with Kawasaki Disease. Therapeutic Apheresis and Dialysis.
[Google Scholar] [CrossRef] [PubMed]
[24] Sonoda, K., Mori, M., Hokosaki, T., et al. (2014) Infliximab plus Plasma Exchange Rescue Therapy in Kawasaki Disease. The Journal of Pediatrics, 164, 1128-1132.
[Google Scholar] [CrossRef] [PubMed]
[25] Crandall, W.V. and Mackner, L.M. (2003) Infusion Reactions to Infliximab in Children and Adolescents: Frequency, Outcome and a Predictive Model. Alimentary Pharmacology & Therapeutics, 17, 75-84.
[Google Scholar] [CrossRef] [PubMed]
[26] Chen, W.T., Huang, S.R. and Wang, J.K. (2003) Kawasaki Disease Presenting with Hepatitis and Prolonged Fever: Report of One Case. Acta Paediatrica Taiwanica, 44, 174-176.
[27] Ierardi, E., Valle, N.D., Nacchiero, M.C., et al. (2006) Onset of Liver Damage after a Single Administration of Infliximab in a Patient with Refractory Ulcerative Colitis. Clinical Drug Investigation, 26, 673-676.
[Google Scholar] [CrossRef] [PubMed]
[28] Ozorio, G., McGarity, B., Bak, H., Jordan, A.S., Lau, H. and Marshall, C. (2007) Autoimmune Hepatitis Following Infliximab Therapy for Ankylosing Spondylitis. The Medical Journal of Australia, 187, 524-526.
[Google Scholar] [CrossRef] [PubMed]
[29] Mori, M., Hara, T., Kikuchi, M., et al. (2018) Infliximab versus Intravenous Immunoglobulin for Refractory Kawasaki Disease: A Phase 3, Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Trial. Scientific Reports, 8, Article No. 1994.
[Google Scholar] [CrossRef] [PubMed]
[30] Keane, J., Gershon, S., Wise, R.P., et al. (2001) Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor Alpha-Neutralizing Agent. The New England Journal of Medicine, 345, 1098-1104.
[Google Scholar] [CrossRef]